ReviewIntractable & rare diseases research2026
Health technology assessment and medical insurance access for rare disease drugs in China: A policy review with quantitative insights from publicly available data.
Dandan Ai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.